Recente publicaties
- launch Takemura, K., Lemelin, A., Ernst, M.S., Wells, J.C., Saliby, R.M., El Zarif, T., Labaki, C., Basappa, N.S., Szabados, B., Powles, T., Davis, I.D., Wood, L.A., Lalani, A-K.A., McKay, R.R., Lee, J-L., Meza, L., Pal, S.K., Donskov, F., Yuasa, T., Beuselinck, B., Gebrael, G., Agarwal, N., Choueiri, T.K., Heng, D.Y C. (2024). Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. doi: 10.1016/j.eururo.2024.01.006 via repository
- launch Sprooten, J., Laureano, R.S., Vanmeerbeek, I., Govaerts, J., Naulaerts, S., Borras, D.M., Kinget, L., Fucikova, J., Spisek, R., Jelinkova, L.P., Kepp, O., Kroemer, G., Krysko, D.V., Coosemans, A., Vaes, R.D W., De Ruysscher, D., De Vleeschouwer, S., Wauters, E., Smits, E., Tejpar, S., Beuselinck, B., Hatse, S., Wildiers, H., Clement, P.M., Vandenabeele, P., Zitvogel, L., Garg, A.D. with Garg, A.D. (corresp. author) (2023). Trial watch: chemotherapy-induced immunogenic cell death in oncology. ONCOIMMUNOLOGY, 12 (1), Art.No. ARTN 2219591. doi: 10.1080/2162402X.2023.2219591 via repository
- launch Takemura, K., Yuasa, T., Lemelin, A., Ferrier, E., Wells, J.C., Saad, E., Saliby, R.M., Basappa, N.S., Wood, L.A., Jude, E., Pal, S.K., Donskov, F., Beuselinck, B., Szabados, B.E., Powles, T.B., Mckay, R.R., Gebrael, G., Agarwal, N., Choueiri, T.K., Heng, D.Y C. (2023). Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC). In: ANNALS OF ONCOLOGY: vol. 34, (S1558-S1559). Presented at the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 01 Dec 2023-03 Dec 2023. doi: 10.1016/j.annonc.2023.10.349
- launch Kinget, L., Naulaerts, S., Govaerts, J., Vanmeerbeek, I., Sprooten, J., Laureano, R.S., Roussel, E., Verbiest, A.T L., Lambrechts, D., Boeckx, B., Zucman-Rossi, J., Albersen, M., Baldewijns, M., Tejpar, S., Beuselinck, B., Garg, A.D. (2023). Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB). In: ANNALS OF ONCOLOGY: vol. 34, (S1026-S1027). Presented at the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 20 Oct 2023-24 Oct 2023. doi: 10.1016/j.annonc.2023.09.1137 via repository
- launch Lemelin, A., Takemura, K., Boyne, D.J., Warkentin, M.T., Brenner, D.R., Cheun, W.Y., Wells, J.C., Labaki, C., McGregor, B.A., Basappa, N.S., Meza, L.A., Pal, S.K., Beuselinck, B., Mckay, R.R., Szabados, B.E., Powles, T.B., Yuasa, T., Ludwig, L., Choueiri, T.K., Heng, D.Y C. (2023). Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC). In: ANNALS OF ONCOLOGY: vol. 34, (S1023-S1024). Presented at the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 20 Oct 2023-24 Oct 2023. doi: 10.1016/j.annonc.2023.09.1132
- launch Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J.B A G., Gurney, H.P., Ravilla, R., Van der Veldt, A.A M., Beuselinck, B., Pokataev, I., Suelmann, B.B., Tuthill, M., Vaena, D., Zagouri, F., Wu, J., Liu, Y., Perini, R., Merchan, J.R., Atkins, M.B. (2023). Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. In: ANNALS OF ONCOLOGY: vol. 34, (S1011-S1011). Presented at the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 20 Oct 2023-24 Oct 2023. doi: 10.1016/j.annonc.2023.09.1111
- launch Poelman, A., Neerinckx, B., Beuselinck, B., De Langhe, E. with De Langhe, E. (corresp. author) (2023). Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature. ACTA CLINICA BELGICA, 78 (5), 410-417. doi: 10.1080/17843286.2023.2183577
- launch Haaker, L., Baldewijns, M., De Wever, L., Albersen, M., Debruyne, P.R., Wynendaele, W., De Meerleer, G., Beuselinck, B. with Beuselinck, B. (corresp. author) (2023). Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. CLINICAL GENITOURINARY CANCER, 21 (4), 442-451. doi: 10.1016/j.clgc.2023.03.003
- launch Duarte, C., Hu, J., Beuselinck, B., Panian, J., Weise, N., Dizman, N., Collier, K.A., Rathi, N., Li, H., Elias, R., Martinez-Chanza, N., Rose, T.L., Harshman, L.C., Gopalakrishnan, D., Vaishampayan, U., Zakharia, Y., Narayan, V., Carneiro, B.A., Mega, A., Singla, N., Meguid, C., George, S., Brugarolas, J., Agarwal, N., Mortazavi, A., Pal, S., McKay, R.R., Lam, E.T. with Lam, E.T. (corresp. author) (2023). Metastatic renal cell carcinoma to the pancreas and other sites -a multicenter retrospective study. ECLINICALMEDICINE, 60, Art.No. ARTN 102018. doi: 10.1016/j.eclinm.2023.102018
- launch Labaki, C., Bakouny, Z., Lemelin, A., Ernst, M.S., Takemura, K., Wells, J.C., Pal, S.K., Szabados, B., Beuselinck, B., McKay, R.R., Lee, J-L., Yuasa, T., Parnis, F., Bjarnason, G.A., McGregor, B.A., Braun, D.A., Xie, W., Xu, W., Heng, D.Y C., Choueiri, T.K. (2023). Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). In: JOURNAL OF CLINICAL ONCOLOGY: vol. 41 (16). Presented at the Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 Jun 2023-06 Jun 2023.
- E03N2A Advances in Oncology – Focus on Cancer Therapy
- E06S8A Aanvullingen in de medische oncologie
- E00U2A Probleemoplossend vermogen en vaardigheden in de medische oncologie
- E0C12A Hemato-oncologie
- E0AM6A Probleemoplossend vermogen in de interne geneeskunde, deel 1
- E06S8B Aanvullingen in de medische oncologie
- E0AX2A Probleemoplossend vermogen in de interne geneeskunde, deel 2
- E0BB2A Probleemoplossend vermogen in de interne geneeskunde, deel 3
- E0BS0A Probleemoplossend vermogen in de medische oncologie, deel 1
- E0BT8A Probleemoplossend vermogen in de medische oncologie, deel 2
- E0BX0A Probleemoplossend vermogen in de medische oncologie, deel 3